Abstract 7145
Background
NRG1 fusions are oncogenic drivers across various cancers. NRG1 fusion proteins bind to HER3, leading to HER2/HER3 heterodimerization, increased downstream signaling, and tumor growth. Clinical responses to anti-HER3 antibodies or HER2 tyrosine kinase inhibitors have been reported. In contrast to these agents, MCLA-128 is a HER2/HER3 bispecific antibody that blocks both NRG1 binding and HER2/3 dimerization. MCLA-128 has demonstrated potent in vitro and in vivo activity in NRG1-fusion positive models. These data support the evaluation of MCLA-128 in patients with NRG1 fusion-positive tumors using a basket approach.
Trial design
This is a global, open-label, multicenter phase 2 basket trial of MCLA-128 in patients with solid tumors harboring NRG1 gene fusions. Main eligibility criteria are locally advanced unresectable or metastatic cancers harboring an NRG1 fusion, and failure under prior standard therapy appropriate for the tumor type and disease stage. Genomic screening of tumor tissue is done at a local laboratory (with post-hoc central confirmation) or central laboratory (RNA sequencing). Three NRG1 fusion-positive tumor cohorts are being evaluated: pancreatic cancer, NSCLC, and other solid tumors. The sample size for the first two cohorts is up to 25 patients; the basket group may enroll up to 40 patients. The primary endpoint for all cohorts is investigator-assessed objective response rate (RECIST v1.1). The key secondary endpoint is duration of response. Other secondary endpoints include progression-free and overall survival. Eligible patients receive a bi-weekly dosing regimen of 750 mg of MCLA-128 (2-hour infusion), every 2 weeks, in 4-week cycles. The study is actively accruing patients in North America, Europe, and Asia.
Clinical trial identification
NCT02912949.
Editorial acknowledgement
Sarah Mackenzie (PhD) from Oncology Therapeutics Development.
Legal entity responsible for the study
Merus N.V.
Funding
Merus N.V.
Disclosure
A. Drilon: Honoraria (self), Advisory / Consultancy: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint, Helsinn, Beigene, BergenBio, Hengrui, Exelixis, Tyra, Verastem, MORE Health; Research grant / Funding (institution): GlaxoSmithKline, Teva, Taiho, PharmaMar; Research grant / Funding (self): Foundation Medicine; Non-remunerated activity/ies: Wolters Kluwer, Merck, Puma . T. Macarulla Mercade: Honoraria (self): Shire Pharmaceuticals, Roche, Tesaro, Batxer, Sanofi, Celgene, QED Therapeutics, Genzyme Europe, Baxalta, Bayer, Incyte, Servier, Lilly, Ipsen; Travel / Accommodation / Expenses: Merck, H3 Biomedicine, Bayer, Sanofi, Servier. E.M. O’Reilly: Research grant / Funding (institution): Genentech, BMS, Halozyme, Celgene, MabVax Therapeutics, ActaBiologica, AstraZeneca, Silenseed, Pfizer, Polaris; Advisory / Consultancy: CytomX Therapeutics, BioLineRx, Targovax, Ipsen, Celgene, Bayer, Polaris, Sobi, Merck. J.A. Rodon: Travel / Accommodation / Expenses: European Journal of Cancer, Vall d’Hebron Institut of Oncology, Chinese University of Hong Kong, SOLTI, Elsevier, GlaxoSmithKline, ESMO, US Department of Defense, Louissiana State University, Hunstman Cancer Institute, Cancer Core Europe, Karolinska Cancer; Advisory / Consultancy: Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Roche Pharmaceuticals, Ellipses Pharma; Research grant / Funding (institution): Bayer and Novartis; Non-remunerated activity/ies: Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GlaxoSmithKline, Ipsen. B.M. Wolpin: Research grant / Funding (institution): Celgene Inc., Eli Lilly and Company; Advisory / Consultancy: BioLineRx Ltd., Celgene Inc., G1 Therapeutics Inc., and GRAIL Inc. S.I. Ou: Honoraria (self): Pfizer, Roche/Genentech/Ignyta/Foundation Medicine, Astra Zeneca, Merck, Takeda/ARIAD; Advisory / Consultancy: Turning Point (TP) Therapeutics; Shareholder / Stockholder / Stock options: Turning Point Therapeutics. J.C. Yang: Honoraria (self): Boehringer Ingelheim, Eli Lilly, Bayer, Roche/, Chugai, Astellas, Merck Serono, MSD, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceuticals, Daiichi Sankyo, Hansoh Pharmaceuticals, Takeda Pharmaceuticals, Blueprint Medicines. A. Varga: Research grant / Funding (institution): Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Research grant / Funding (institution), drug supply: Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. A.J. de Langen: Research grant / Funding (institution): Boehringer, AstraZeneca, Merck / MSD, BMS; Non-remunerated activity/ies, non-financial support: Roche; Honoraria (self): Merck / MSD, BMS. V. Boni: Honoraria (self), Research grant / Funding (institution): Loxo Therapeutics; Advisory / Consultancy: OncoArt; Advisory / Consultancy: Guidepoint; Speaker Bureau / Expert testimony: SOLTI; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): PUMA; Research grant / Funding (institution): Kura; Research grant / Funding (institution): Cytomex; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Seattle Genetics; Travel / Accommodation / Expenses: START. M. Duruisseaux: Advisory / Consultancy, Research grant / Funding (institution), Personal fees for expertise / Consulting : Pfizer; Advisory / Consultancy, Research grant / Funding (institution), Personal fees for expertise / Consulting : Novartis; Research grant / Funding (institution): Nanostring; Advisory / Consultancy, Personal fees for expertise / Consulting : Roche; Advisory / Consultancy, Personal fees for expertise / Consulting : Takeda; Advisory / Consultancy, Personal fees for expertise / Consulting: AbbVie; Advisory / Consultancy, Personal fees for expertise / Consulting: MSD; Advisory / Consultancy, Personal fees for expertise / Consulting : BI; Advisory / Consultancy, Personal fees for expertise / Consulting : BMS; Advisory / Consultancy, Personal fees for expertise / Consulting : AZ. S.V. Liu: Advisory / Consultancy: Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Heron, Ignyta, Inivata, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho (DSMB), Takeda/Ariad, Tempus; Research grant / Funding (institution): Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, Corvus, Debiopharm, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics. E. Wasserman: Full / Part-time employment: Merus NV; Shareholder / Stockholder / Stock options: Merus NV. D.M. Hyman: Shareholder / Stockholder / Stock options: Fount; Consulting or Advisory Role: Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Genentech, Fount; Research grant / Funding (institution): AstraZeneca, Puma Biotechnology, Loxo, Bayer; Travel, Accommodations, Expenses: Genentech, Chugai Pharma. J. Tabernero: Advisory / Consultancy: Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Part. All other authors have declared no conflicts of interest.
Resources from the same session
1988 - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix
Presenter: Semir Vranic
Session: Poster Display session 2
Resources:
Abstract
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract